

Anil Kapoor

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2003017/anil-kapoor-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

331
papers

10,473
citations

38
h-index

97
g-index

393
ext. papers

12,939
ext. citations

3.2
avg. IF

6.37
L-index

#	Paper	IF	Citations
331	Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2007 , 356, 2271-81	59.2	3025
330	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015 , 372, 2387-97	59.2	2371
329	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1289-1300	59.2	263
328	Role of computed tomography with no contrast medium enhancement in predicting the outcome of extracorporeal shock wave lithotripsy for urinary calculi. <i>BJU International</i> , 2005 , 95, 1285-8	5.6	143
327	Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. <i>BJU International</i> , 2012 , 110, 510-6	5.6	124
326	Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. <i>Journal of Urology</i> , 2019 , 202, 282-289	2.5	101
325	Apoptotic release of histones from nucleosomes. <i>Journal of Biological Chemistry</i> , 2002 , 277, 12001-8	5.4	90
324	Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. <i>PLoS ONE</i> , 2013 , 8, e70047	3.7	88
323	Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011 , 1813, 683-94	4.9	85
322	Prostate cancer update from the American Society of Clinical Oncology (ASCO) annual meeting 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, 137	1.2	78
321	Update from the European Association of Urology (EAU) Annual Meeting 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, 123	1.2	78
320	Update from the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium (ASCO-GU). <i>Canadian Urological Association Journal</i> , 2017 , 11, 159	1.2	78
319	Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 913-920	13.4	78
318	Current Concepts in Genitourinary Oncology: GU-ASCO 2015. <i>Canadian Urological Association Journal</i> , 2015 , 9, 147	1.2	78
317	Oncology Brief from ASCO 2015: Update on Kidney Cancer and Prostate Cancer. <i>Canadian Urological Association Journal</i> , 2015 , 9, 157	1.2	78
316	Sunitinib: 10 years of clinical experience in the treatment of advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2016 , 10, 235	1.2	78
315	Update on Bladder, Kidney, and Prostate Cancer from the European Society for Medical Oncology (ESMO) Annual Meeting 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, 223	1.2	78

314	Guidelines for the management of the incidentally discovered adrenal mass. <i>Canadian Urological Association Journal</i> , 2011 , 5, 241-7	1.2	75
313	The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015 , 9, 90-6	1.2	70
312	Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. <i>Prostate</i> , 1997 , 32, 129-39	4.2	65
311	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. <i>Oncotarget</i> , 2015 , 6, 1900-19	3.3	65
310	Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. <i>Blood</i> , 2015 , 125, 195-8	2.2	63
309	Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 3618-30	6.4	63
308	Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells. <i>Journal of Biological Chemistry</i> , 2007 , 282, 22052-61	5.4	63
307	Laparoscopic versus open partial nephrectomy. <i>Urology</i> , 2004 , 64, 458-61	1.6	60
306	Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. <i>European Urology</i> , 2008 , 54, 866-73	10.2	59
305	Conditional survival after radical nephroureterectomy for upper tract carcinoma. <i>European Urology</i> , 2015 , 67, 803-12	10.2	54
304	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. <i>PLoS ONE</i> , 2017 , 12, e0173358	3.7	52
303	Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008 , 1782, 642-8	6.9	46
302	Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. <i>BJU International</i> , 2017 , 119, 543-549	5.6	45
301	βMannosidase 2C1 attenuates PTEN function in prostate cancer cells. <i>Nature Communications</i> , 2011 , 2, 307	17.4	45
300	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016 , 94, 154-60	1.6	45
299	Intact specimen extraction in laparoscopic nephrectomy procedures: Pfannenstiel versus expanded port site incisions. <i>Urology</i> , 2007 , 69, 241-4	1.6	43
298	The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. <i>Urology</i> , 2012 , 79, 840-5	1.6	42
297	The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. <i>Cancers</i> , 2019 , 11,	6.6	41

296	Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 975-87	3.5	40
295	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 31.e17-24	2.8	39
294	IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012 , 1822, 875-84	6.9	39
293	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. <i>BJU International</i> , 2013 , 112, 791-7	5.6	38
292	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018 , 124, 3677-3683	6.4	38
291	PTEN inhibits BMI1 function independently of its phosphatase activity. <i>Molecular Cancer</i> , 2009 , 8, 98	42.1	37
290	ATM activity contributes to the tumor-suppressing functions of p14ARF. <i>Oncogene</i> , 2004 , 23, 7355-65	9.2	37
289	Spontaneous fractures in the mouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1597-610	6.3	37
288	Canadian guidelines for the management of small renal masses (SRM). <i>Canadian Urological Association Journal</i> , 2015 , 9, 160-3	1.2	36
287	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. <i>Cancer Research</i> , 2016 , 76, 1603-14	10.1	35
286	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 839-45	2.8	35
285	Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. <i>Journal of Biological Chemistry</i> , 2010 , 285, 28912-23	5.4	35
284	The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	34
283	Robot-assisted laparoscopic renal artery aneurysm reconstruction. <i>Journal of Vascular Surgery</i> , 2006 , 44, 651-3	3.5	33
282	Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. <i>European Journal of Cancer</i> , 2017 , 70, 62-74	7.5	32
281	Malignancy in kidney transplant recipients. <i>Drugs</i> , 2008 , 68 Suppl 1, 11-9	12.1	32
280	Comparison of laparoscopic radical renal surgery in morbidly obese and non-obese patients. <i>Journal of Endourology</i> , 2004 , 18, 657-60	2.7	32
279	Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. <i>Journal of Oncology Practice</i> , 2013 , 9, e262-7	3.1	31

278	ATM activation is accompanied with earlier stages of prostate tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006 , 1763, 1090-7	4.9	31
277	Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. <i>Urology</i> , 2006 , 68, 514-7	1.6	31
276	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1161-5	2.8	30
275	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014 , 8, E845-52	1.2	29
274	Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus. <i>Urology</i> , 2014 , 83, 812-6	1.6	29
273	Transfer of laparoscopic radical prostatectomy skills from bench model to animal model: a prospective, single-blind, randomized, controlled study. <i>Journal of Urology</i> , 2012 , 187, 1861-6	2.5	29
272	An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies. <i>Acta Cirurgica Brasileira</i> , 2013 , 28, 870-6	1.6	29
271	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017 , 35, 355-365	4	27
270	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015 , 116, 72-8	5.6	26
269	Contributions of DNA Damage to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	26
268	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 486.e1-486.e7	2.8	25
267	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017 , 49, 2143-2149	2.3	25
266	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017 , 11, 112-117	1.2	25
265	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. <i>Canadian Urological Association Journal</i> , 2014 , 8, E398-412	1.2	25
264	Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007 , 1772, 1134-42	6.9	25
263	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , 2019 , 5, 488-496	5.1	25
262	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 441-8	2.8	23
261	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013 , 7, 319-23	1.2	23

260	Amplification of MUC1 in prostate cancer metastasis and CRPC development. <i>Oncotarget</i> , 2016 , 7, 83115-83133	5.9	23
259	Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression. <i>Neoplasia</i> , 2017 , 19, 857-867	6.4	22
258	Benign prostatic hyperplasia (BPH) management in the primary care setting. <i>Canadian Journal of Urology</i> , 2012 , 19 Suppl 1, 10-7	0.8	22
257	Results of the ADAPT Phase 3 Study of Rocabudencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2327-2336	12.9	21
256	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2019 , 230-238	1.2	21
255	High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. <i>Histopathology</i> , 2019 , 75, 440-442	7.3	20
254	Upregulation of FAM84B during prostate cancer progression. <i>Oncotarget</i> , 2017 , 8, 19218-19235	3.3	20
253	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019 , 108, 69-77	7.5	20
252	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018 , 121, 383-392	5.6	19
251	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 486.e17-486.e23	2.8	19
250	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). <i>Urology</i> , 2016 , 89, 19-26	1.6	19
249	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019 , 15, 1683-1695	3.6	19
248	Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. <i>European Journal of Cancer</i> , 2013 , 49, 3537-46	7.5	19
247	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T N M renal cell carcinoma. <i>World Journal of Urology</i> , 2017 , 35, 1899-1905	4	19
246	Adenovirus-mediated gene transfer of TGF- β 1 to the renal glomeruli leads to proteinuria. <i>American Journal of Pathology</i> , 2012 , 180, 940-951	5.8	19
245	Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. <i>Canadian Urological Association Journal</i> , 2009 , 3, 143-9	1.2	18
244	Management of kidney cancer: canadian kidney cancer forum consensus update 2011. <i>Canadian Urological Association Journal</i> , 2012 , 6, 16-22	1.2	18
243	A Prospective Study of ¹⁸ F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 546-555	4	18

242	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017 , 11, 182-187	1.2	17
241	Contemporary agents in the management of metastatic castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, E414-E423	1.2	17
240	Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. <i>Canadian Urological Association Journal</i> , 2013 , 7, 108-113	1.2	16
239	Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2011 , 18, 5-10	2.8	16
238	Electrical stimulation with non-implanted electrodes for overactive bladder in adults. <i>The Cochrane Library</i> , 2016 , 12, CD010098	5.2	16
237	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015 , 9, 164-70	1.2	15
236	Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. <i>Canadian Urological Association Journal</i> , 2007 , 1, 27-38	1.2	15
235	Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study. <i>Urology</i> , 2015 , 86, 1174-8	1.6	14
234	Electrical stimulation with non-implanted electrodes for overactive bladder in adults. <i>Cochrane Database of Systematic Reviews</i> , 2016 , 4, CD010098		14
233	Task-specific bench model training versus basic laparoscopic skills training for laparoscopic radical prostatectomy: a randomized controlled study. <i>Canadian Urological Association Journal</i> , 2009 , 3, 22-30	1.2	14
232	Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2016 , 20, 82-8	1.7	14
231	Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. <i>Current Oncology</i> , 2018 , 25, e576-e584	2.8	14
230	A Prospective Randomized Study of Pfannenstiel Versus Expanded Port Site Incision for Intact Specimen Extraction in Laparoscopic Radical Nephrectomy. <i>Journal of Endourology</i> , 2015 , 29, 913-8	2.7	13
229	Treatment of adult rhabdoid renal cell carcinoma with sorafenib. <i>Canadian Urological Association Journal</i> , 2008 , 2, 631-4	1.2	13
228	Laparoscopic nephrectomy with intact specimen extraction for polycystic kidney disease. <i>Journal of Endourology</i> , 2008 , 22, 675-80	2.7	13
227	Update on cryoablation for treatment of small renal mass: oncologic control, renal function preservation, and rate of complications. <i>Current Urology Reports</i> , 2014 , 15, 396	2.9	12
226	Use of SNAPPS Model for Pediatric Outpatient Education. <i>Indian Pediatrics</i> , 2017 , 54, 288-290	1.2	12
225	Update on medical expulsive therapy for distal ureteral stones: Beyond alpha-blockers. <i>Canadian Urological Association Journal</i> , 2014 , 8, 442-5	1.2	12

224	CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. <i>Canadian Urological Association Journal</i> , 2013 , 7, 231-7	1.2	12
223	Inhibition of mTOR in kidney cancer. <i>Current Oncology</i> , 2009 , 16 Suppl 1, S33-9	2.8	12
222	Prostate cancer screening: Attitudes and practices of family physicians in Ontario. <i>Canadian Urological Association Journal</i> , 2012 , 6, 188-93	1.2	12
221	Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2014 , 5, 7406-19	3.3	12
220	Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. <i>Journal of Urology</i> , 2020 , 204, 671-676	2.5	12
219	Current management of metastatic renal cell carcinoma: evolving new therapies. <i>Current Opinion in Supportive and Palliative Care</i> , 2017 , 11, 231-237	2.6	11
218	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. <i>Journal of Biological Chemistry</i> , 2017 , 292, 21180-21192	5.4	11
217	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018 , 36, 51-57	4	11
216	Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 257-271	3.2	11
215	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018 , 12, E325-E330	1.2	11
214	Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018 , 12, 173-180	1.2	11
213	Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic. <i>Current Oncology</i> , 2018 , 25, e220-e223	2.8	11
212	Outcome of third renal allograft retransplants versus primary transplants from paired donors. <i>Transplantation</i> , 2009 , 87, 1214-20	1.8	11
211	Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 234-8	1.6	11
210	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2020 , 14, 17-23	1.2	11
209	Comparison of laparoscopic and open nephrectomy for adult polycystic kidney disease: operative challenges and technique. <i>Canadian Journal of Urology</i> , 2006 , 13, 3340-5	0.8	11
208	Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 721-726	2.8	10
207	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2019 , 33, 606-613	2.7	10

206	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020 , 121, 688-696	2.8	10
205	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 176-183	3.3	10
204	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018 , 12, 231-238	1.2	10
203	Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum. <i>Canadian Urological Association Journal</i> , 2020 , 14, E137-E149	1.2	10
202	Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers. <i>Canadian Urological Association Journal</i> , 2017 , 11, E138-E142	1.2	10
201	. <i>Canadian Urological Association Journal</i> , 2009 , 3, 200-204	1.2	10
200	Renal histopathology features according to various warm ischemia times in porcine laparoscopic and open surgery model. <i>Canadian Urological Association Journal</i> , 2011 , 5, 40-3	1.2	10
199	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , 2019 , 5, 467-473 ^{5.1}	5.1	10
198	Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells. <i>Prostate</i> , 2018 , 78, 953-961	4.2	10
197	CYB5D2 displays tumor suppression activities towards cervical cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 556-565	6.9	9
196	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019 , 13, 307-314	1.2	9
195	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 269-269	2.2	9
194	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018 , 56, 118-125	2.8	9
193	FAM84B promotes prostate tumorigenesis through a network alteration. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919846372	5.4	8
192	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019 , 13, 343-354	1.2	8
191	Terminal loop cutaneous ureterostomy in renal transplantation: an under utilized urinary diversion technique. <i>Journal of Urology</i> , 2005 , 174, 1906-9; discussion 1909	2.5	8
190	Assessment of biochemical recurrence of prostate cancer (Review). <i>International Journal of Oncology</i> , 2019 , 55, 1194-1212	4.4	8
189	Review of the efficacy and safety of cryoablation for the treatment of small renal masses. <i>Canadian Urological Association Journal</i> , 2013 , 7, E38-44	1.2	8

188	Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4502-4502	2.2	8
187	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018 , 54, 112-118	2.8	8
186	Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development. <i>Translational Oncology</i> , 2018 , 11, 1012-1022	4.9	8
185	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. <i>Journal of Endourology</i> , 2017 , 31, 645-650	2.7	7
184	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. <i>Journal of Endourology</i> , 2018 , 32, 621-629	2.7	7
183	Surgical management of stage T1 renal tumours at Canadian academic centres. <i>Canadian Urological Association Journal</i> , 2015 , 9, 99-106	1.2	7
182	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4596-TPS4596	2.2	7
181	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021 , 205, 78-85	2.5	7
180	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2019 , 13, 166-174	1.2	7
179	Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis. <i>Canadian Urological Association Journal</i> , 2019 , 13, 15-23	1.2	7
178	SDH-deficient renal cell carcinoma - clinical, pathologic and genetic correlates: a case report. <i>BMC Urology</i> , 2018 , 18, 109	2.2	7
177	Probiotics for the treatment of depression and anxiety: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2021 , 45, 75-90	1.3	7
176	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. <i>Kidney Cancer</i> , 2017 , 1, 31-40	0.6	6
175	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, 310-320	1.2	6
174	Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice. <i>Canadian Urological Association Journal</i> , 2018 , 12, E53-E58	1.2	6
173	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. <i>Journal of Urology</i> , 2018 , 200, 335-343	2.5	6
172	Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2013 , 7, 306-11	1.2	6
171	Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. <i>Canadian Urological Association Journal</i> , 2013 , 7, 238-43	1.2	6

170	Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2011 , 5, 211-21	2.6	6
169	Renal cell carcinoma in renal allograft: Case series and review of literature. <i>Urology Annals</i> , 2018 , 10, 229-232	1	6
168	Commercial renal transplantation: A risky venture? A single Canadian centre experience. <i>Canadian Urological Association Journal</i> , 2011 , 5, 335-40	1.2	6
167	18F-DCFPyL PET/CT in Oncocytoma. <i>Clinical Nuclear Medicine</i> , 2018 , 43, 921-924	1.7	6
166	Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. <i>Current Oncology</i> , 2018 , 25, e444-e453	2.8	6
165	The true malignancy risk of Bosniak III cystic renal lesions: Active surveillance or surgical resection?. <i>Canadian Urological Association Journal</i> , 2018 , 12, E276-E280	1.2	6
164	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	6
163	The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert. <i>Genes</i> , 2020 , 11,	4.2	5
162	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017 , 11, 232-237	1.2	5
161	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2018 , 12, 243-251	1.2	5
160	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1973-1980	4	5
159	Angiosarcoma of the adrenal gland with concurrent contralateral advanced renal cell carcinoma: A diagnostic and management dilemma. <i>Canadian Urological Association Journal</i> , 2015 , 9, E302-5	1.2	5
158	Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. <i>Canadian Urological Association Journal</i> , 2015 , 9, 397-402	1.2	5
157	Laparoscopic pyeloplasty: the updated McMaster University experience. <i>Canadian Urological Association Journal</i> , 2008 , 2, 388-91	1.2	5
156	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4516-4516	2.2	5
155	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 608-608	2.2	5
154	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. <i>Canadian Urological Association Journal</i> , 2012 , 6, 455-62	1.2	5
153	Next Generation Quality: Assessing the Physician in Clinical History Completeness and Diagnostic Interpretations Using Funnel Plots and Normalized Deviations Plots in 3,854 Prostate Biopsies. <i>Journal of Pathology Informatics</i> , 2017 , 8, 43	4.4	5

152	IQGAP2 Displays Tumor Suppression Functions. <i>Journal of Analytical Oncology</i> , 2015 , 4, 86-93		5
151	Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 799.e1-799.e10	2.8	5
150	Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis. <i>Genes</i> , 2020 , 11,	4.2	5
149	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e730-e738	3.3	4
148	Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle. <i>Data in Brief</i> , 2016 , 6, 811-6	1.2	4
147	Laparoscopic nephrectomy for massive polycystic kidney disease: Updated technique and outcomes. <i>Canadian Urological Association Journal</i> , 2014 , 8, 341-5	1.2	4
146	Laparoscopic partial nephrectomy: a challenging operation with a steep learning curve. <i>Canadian Urological Association Journal</i> , 2009 , 3, 119	1.2	4
145	Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 157-65	2.6	4
144	Effect of F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.. <i>Radiology</i> , 2022 , 211824	20.5	4
143	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS684-TPS684	2.2	4
142	Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population. <i>Canadian Urological Association Journal</i> , 2020 , 14, E499-E506	1.2	4
141	First-line treatment options in metastatic renal cell cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, S236-S238	1.2	4
140	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. <i>Canadian Urological Association Journal</i> , 2019 , 13, 377-383	1.2	4
139	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of F-DCFPyL PET/CT Restaging. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100553	3.3	4
138	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1430-1437	8.9	4
137	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2021 ,	5.1	4
136	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2021 , 15, E81-E90	1.2	4
135	Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. <i>Clinical Drug Investigation</i> , 2018 , 38, 1155-1165	3.2	4

134	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022 , 207, 16-24	2.5	4
133	Circulating microvesicle protein is associated with renal transplant outcome. <i>Transplant Immunology</i> , 2019 , 55, 101210	1.7	3
132	Renal tumour scoring systems: How useful are they?. <i>Canadian Urological Association Journal</i> , 2015 , 9, 46-7	1.2	3
131	Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. <i>Canadian Urological Association Journal</i> , 2017 , 11, E222-E232	1.2	3
130	Laparoscopic partial nephrectomy: The McMaster University experience. <i>Canadian Urological Association Journal</i> , 2012 , 6, 233-6	1.2	3
129	Specific reduction of fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma. <i>Cancer Investigation</i> , 2009 , 27, 836-43	2.1	3
128	Identification of a novel Wee1 isoform. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005 , 1729, 1-9		3
127	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4597-TPS4597	2.2	3
126	509: The Natural History of Small Renal Masses: A Prospective Multi-Center Canadian Trial. <i>Journal of Urology</i> , 2007 , 177, 169-170	2.5	3
125	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 314-321.e1	3.3	3
124	Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?. <i>Translational Oncology</i> , 2020 , 13, 241-244	4.9	3
123	Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports. <i>PLoS ONE</i> , 2021 , 16, e0253876	3.7	3
122	Kidney cancer, ESMO 2016. <i>Canadian Urological Association Journal</i> , 2016 , 10, S227-S230	1.2	3
121	Chemotherapy research for metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, S140-S143	1.2	3
120	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. <i>BMJ Open</i> , 2019 , 9, e025662	3	3
119	Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome. <i>Cancer Management and Research</i> , 2019 , 11, 9307-9319	3.6	3
118	Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. <i>Clinical Oncology</i> , 2020 , 32, e10-e15	2.8	3
117	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e610-e618	3.3	3

116	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. <i>Surgical Oncology</i> , 2021 , 38, 101588	2.5	3
115	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. <i>Canadian Urological Association Journal</i> , 2019 , E377-E381	1.2	2
114	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. <i>European Urology Focus</i> , 2021 , 7, 818-826	5.1	2
113	Immunohistochemistry Use by Diagnostic Category and Pathologist in 4477 Prostate Core Biopsy Sets Assessed at Two Hospitals. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020 , 28, 259-266	1.9	2
112	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020 , 47, 271-280	2.9	2
111	Management of complex renal cysts in Canada: results of a survey study. <i>BMC Urology</i> , 2020 , 20, 47	2.2	2
110	Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. <i>Canadian Urological Association Journal</i> , 2018 , 12, E415-E420	1.2	2
109	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. <i>Canadian Urological Association Journal</i> , 2020 , 14, 24-30	1.2	2
108	What's New in Prostate Cancer Research? Highlights of GU-ASCO 2015. <i>Canadian Urological Association Journal</i> , 2015 , 9, S148-53	1.2	2
107	The robotic invasion of Canada. <i>Canadian Urological Association Journal</i> , 2014 , 8, E466-7	1.2	2
106	Told you so! Examining the impact of the surgical safety checklist. <i>Canadian Urological Association Journal</i> , 2014 , 8, 79	1.2	2
105	What's new in prostate cancer research? Highlights of GU-ASCO 2014. <i>Canadian Urological Association Journal</i> , 2014 , 8, S8-S12	1.2	2
104	PSA screening: And now a message from our experts. <i>Canadian Urological Association Journal</i> , 2014 , 8, 387-8	1.2	2
103	A system for laparoscopic surgery ergonomics and skills evaluation. <i>Journal of Endourology</i> , 2011 , 25, 1111-4	2.7	2
102	Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. <i>Current Oncology</i> , 2009 , 16,	2.8	2
101	Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Metastatic Disease in Patients with Clear Cell Renal Cell Carcinoma. <i>Current Urology</i> , 2009 , 2, 188-193	1.7	2
100	A platform of high-efficiency nonviral gene transfer in mouse osteoblast cells in vitro. <i>Molecular Biotechnology</i> , 2006 , 34, 29-35	3	2
99	Canadian Urological Association guideline: Management of small renal masses - Full-text.. <i>Canadian Urological Association Journal</i> , 2022 , 16, E61-E75	1.2	2

98	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4555-4555	2.2	2
97	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4514-4514	2.2	2
96	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 568-568	2.2	2
95	Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas. <i>Canadian Urological Association Journal</i> , 2020 , 14, E527-E536	1.2	2
94	Canadian Urological Association Best Practice Report: Diagnosis and management of sporadic angiomyolipomas. <i>Canadian Urological Association Journal</i> , 2020 , 14, E527-E536	1.2	2
93	Emphysematous pyelonephritis in failed renal allograft: Case report and review of literature. <i>Urology Annals</i> , 2016 , 8, 111-3	1	2
92	Differences between the real and the desired worlds in the results of clinical trials. <i>Clinics</i> , 2015 , 70, 618-23	2	2
91	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 836.e19-836.e27	2.8	2
90	Expert and Crowdsourced Evaluation of Image Quality From a Novel Endoscopy Phone Light Adapter. <i>Urology</i> , 2020 , 146, 54-58	1.6	2
89	Development, implementation, and evaluation of a competency-based didactic and simulation-focused boot camp for incoming urology residents: Report of the first three years. <i>Canadian Urological Association Journal</i> , 2021 , 15, 98-105	1.2	2
88	Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 798.e9-798.e16	2.8	2
87	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. <i>Canadian Urological Association Journal</i> , 2021 , 15, E90-E96	1.2	2
86	Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial. <i>Canadian Urological Association Journal</i> , 2021 , 15, E97-E102	1.2	2
85	Localized prostate cancer. <i>Canadian Urological Association Journal</i> , 2016 , 10, S138-S139	1.2	2
84	Effective Prediction of Prostate Cancer Recurrence through the Network. <i>Cancers</i> , 2021 , 13,	6.6	2
83	McMaster experience with laparoscopic pyeloplasty. <i>Canadian Journal of Urology</i> , 2004 , 11, 2299-302	0.8	2
82	Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes. <i>Canadian Urological Association Journal</i> , 2020 , 14, 337-345	1.2	1
81	Renal cell carcinoma in the Canadian Indigenous population. <i>Current Oncology</i> , 2019 , 26, e367-e371	2.8	1

80	Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2020 , 14, 122-129	1.2	1
79	Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Urology</i> , 2013 , 64, 518-9	10.2	1
78	Renal cell carcinoma and amyopathic dermatomyositis. <i>Canadian Urological Association Journal</i> , 2015 , 9, E340-2	1.2	1
77	What's New in Renal Cell Cancer Research? Highlights of GU-ASCO 2015. <i>Canadian Urological Association Journal</i> , 2015 , 9, S154-5	1.2	1
76	"I told you so": Examining the impact of the surgical safety checklist. <i>Canadian Urological Association Journal</i> , 2014 , 8, E221-2	1.2	1
75	The robotic invasion in Canada. <i>Canadian Urological Association Journal</i> , 2014 , 8, 151	1.2	1
74	New paradigms in the treatment of genitourinary malignancies: GU-ASCO Update 2014. <i>Canadian Urological Association Journal</i> , 2014 , 8, S7	1.2	1
73	Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines. <i>Canadian Urological Association Journal</i> , 2007 , 1, S34-40	1.2	1
72	1491 DESIGNING A HIGH-FIDELITY LAPAROSCOPIC PARTIAL NEPHRECTOMY BENCH MODEL: DETERMINING THE TEAR STRENGTH AND RESISTANCE OF A SYNTHETIC SILICONE COMPOSITION. <i>Journal of Urology</i> , 2011 , 185,	2.5	1
71	Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 85-91	1.6	1
70	Laparoscopic right donor nephrectomy. <i>BJU International</i> , 2009 , 103, 998-1013	5.6	1
69	Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 420-420	2.2	1
68	The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 424-424	2.2	1
67	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS710-TPS710	2.2	1
66	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1340-1347	7.3	1
65	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. <i>Clinical and Translational Radiation Oncology</i> , 2022 , 32, 41-47	4.6	1
64	Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. <i>Current Oncology</i> , 2020 , 28, 226-232	2.8	1
63	Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. <i>Asian Journal of Andrology</i> , 2020 , 22, 437-438	2.8	1

62	Downregulation of the Raf kinase inhibitory protein (RKIP) in clear cell renal cell carcinoma associates with poor prognosis 2020 , 435-457		1
61	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2021 , 15, 132-137	1.2	1
60	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	1
59	Canadian Update on Surgical Procedures (CUSP) Urology Group consensus for intraoperative hemostasis during minimally invasive partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2020 , 14, E387-E393	1.2	1
58	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2021 , 15, 84-97	1.2	1
57	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. <i>Journal of Urology</i> , 2021 , 205, 1303-1309	2.5	1
56	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4596-TPS4596	2.2	1
55	Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 371.e17-371.e25	2.8	1
54	Androgen receptor axis-targeted agents. <i>Canadian Urological Association Journal</i> , 2016 , 10, S146-S148	1.2	1
53	A prospective, randomized, pilot trial of a polyethylene glycol (PEG)-coated collagen patch (Hemopatch) for intraoperative hemostasis during deceased donor renal transplant. <i>Canadian Urological Association Journal</i> , 2020 , 14, E1-E5	1.2	1
52	Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. <i>World Journal of Urology</i> , 2021 , 39, 1569-1575	4	1
51	Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel Towards Prostate Cancer Relapse. <i>Genes</i> , 2021 , 12,	4.2	1
50	Radionuclides. <i>Canadian Urological Association Journal</i> , 2016 , 10, S144-S145	1.2	0
49	Surveillance post-radiofrequency ablation for small renal masses: Recurrence and followup. <i>Canadian Urological Association Journal</i> , 2020 , 14, 398-403	1.2	0
48	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 576.e11-576.e16	2.8	0
47	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. <i>CMAJ Open</i> , 2017 , 5, E834-E841	2.5	0
46	Comparison of laparoscopic donor nephrectomy with open donor nephrectomy: McMaster University experience and operative technique. <i>Indian Journal of Transplantation</i> , 2011 , 5, 191-194	0.2	0
45	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100899	3.3	0

44	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021 , 5, 21-29	0.6	○
43	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 239.e1-239.e7	2.8	○
42	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4554-4554	2.2	○
41	MUCIN 1 in Prostate Cancer125-138		○
40	Use of cannabis in urological cancer patients: A review to evaluate risk for cancer development, therapeutic use, and symptom management. <i>Canadian Urological Association Journal</i> , 2021 , 15, 413-419	1.2	○
39	Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. <i>Canadian Urological Association Journal</i> , 2021 , 15, 353-358	1.2	○
38	Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort Study. <i>Clinical Oncology</i> , 2021 , 33, 468-475	2.8	○
37	The role and timing of cytoreductive nephrectomy in the immunotherapy era. <i>European Urology Focus</i> , 2020 , 6, 7-8	5.1	○
36	Prognostic factors in patients with small renal masses: a comparison between . <i>Cancer Causes and Control</i> , 2021 , 32, 119-126	2.8	○
35	The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 499.e15-499.e22	2.8	○
34	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 962-970	4.2	○
33	Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels. <i>Cancers</i> , 2022 , 14, 2805	6.6	○
32	Reply by the Authors. <i>Urology</i> , 2017 , 100, 255	1.6	
31	Images - Rare diagnosis of high-grade, undifferentiated pelvic sarcoma for urinary dysfunction in a young man. <i>Canadian Urological Association Journal</i> , 2021 , 15, E192-E194	1.2	
30	New research in kidney cancer, ASCO 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, S298-300	1.2	
29	New research in bladder cancer, ASCO 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, S301-2	1.2	
28	Canadian content at GU-ASCO 2014: Highlights of research involving Canadian researchers. <i>Canadian Urological Association Journal</i> , 2014 , 8, S16-8	1.2	
27	What's new in renal cell cancer research? Highlights of GU-ASCO 2014. <i>Canadian Urological Association Journal</i> , 2014 , 8, S13-5	1.2	

26	Uncertainty in ultrasound reporting. <i>Canadian Urological Association Journal</i> , 2007 , 1, 255	1.2
25	Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. <i>Canadian Urological Association Journal</i> , 2013 , 2, 175	1.2
24	Spontaneous regression of an untreated lung cancer. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2010 , 26, 173-175	0.4
23	Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations.. <i>Canadian Urological Association Journal</i> , 2022 , 16, 24-25	1.2
22	Application of Canadian hereditary renal cell carcinoma risk criteria to a population database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 621-621	2.2
21	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4597-TPS4597	2.2
20	A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 161-161	2.2
19	Acute care for renal colic in Canadian healthcare - a commentary on emergency department patient flow metrics and treatment options. <i>Canadian Urological Association Journal</i> , 2020 , 14, 265-266	1.2
18	The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 480-480	2.2
17	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16078-e16078	2.2
16	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16065-e16065	2.2
15	Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4580-4580	2.2
14	Preferred management option for small renal masses: laparoscopic partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2010 , 4, 139-41	1.2
13	Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 434-434	2.2
12	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. <i>Société Internationale D'urologie Journal</i> , 2021 , 2, 82-95	0.1
11	PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5064-5064	2.2
10	What's new in testosterone deficiency research?. <i>Canadian Urological Association Journal</i> , 2016 , 10, S130-S131	1.2
9	Intrinsic ureteral endometriosis as a cause of unilateral obstructive uropathy. <i>Canadian Urological Association Journal</i> , 2016 , 10, E119-21	1.2

- 8 What's new in renal cancer research?. *Canadian Urological Association Journal*, **2016**, 10, S132-S133 1.2
- 7 What's new in prostate cancer research?. *Canadian Urological Association Journal*, **2016**, 10, S127-S129 1.2
- 6 Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer. *Canadian Urological Association Journal*, **2019**, 13, 404-405 1.2
- 5 Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression. *Advances in Stem Cells and Their Niches*, **2021**, 5, 177-204 0.2
- 4 Reply By Authors. *Journal of Urology*, **2021**, 205, 84-85 2.5
- 3 Pathologist workload, work distribution and significant absences or departures at a regional hospital laboratory.. *PLoS ONE*, **2022**, 17, e0265905 3.7
- 2 Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.. *Acta Oncologica*, **2022**, 1-9 3.2
- 1 Practice-changing publications: Kidney cancer.. *Canadian Urological Association Journal*, **2022**, 16, E237-E239